Influence of Immunosuppressive Drugs on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Gap Between Basic Science and Clinical Evidence
Authors:
- Hans J. SchlittHSHans J. Schlitt
- Edward K. GeisslerEGEdward K. Geissler
- 15 June 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 91 (11) , 1173-1176
Abstract
Effects of immunosuppressive drug on tumor development in transplantation are understudied. Tumors are especially concerning when liver transplantation recipients have a pretransplant hepatocellular carcinoma (HCC). Because immunosuppressive drugs likely influence HCC recurrence, with mammalian target of rapamycin inhibitors showing antineoplastic properties especially experimentally, we sought for practical medical guidance from published clinical studies. Although the current literature review revealed 14 studies regarding immunosuppression in this context, suggesting antitumor effects for mammalian target of rapamycin inhibitors, the quality of evidence is low. Therefore, randomized controlled trials investigating effects of immunosuppression on HCC recurrence in liver transplantation are lacking, exposing a gap between basic science knowledge and clinical evidence.Keywords
This publication has 22 references indexed in Scilit:
- A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaBMC Cancer, 2010
- Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice #Hepatology, 2009
- mTOR, Cancer and TransplantationAmerican Journal of Transplantation, 2008
- Sirolimus Therapy in Liver Transplant Patients: An Initial Experience at a Single CenterTransplantation Proceedings, 2008
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patientsWorld Journal of Gastroenterology, 2006
- Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2005
- Cancer after Kidney Transplantation in the United StatesAmerican Journal of Transplantation, 2004
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002